PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 172 filers reported holding PDL BIOPHARMA INC in Q2 2017. The put-call ratio across all filers is 0.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $14,879,000 | -4.5% | 4,723,376 | -11.7% | 0.51% | +8.4% |
Q2 2020 | $15,572,000 | -3.7% | 5,351,132 | -6.7% | 0.47% | -16.3% |
Q1 2020 | $16,169,000 | -14.3% | 5,733,572 | -1.3% | 0.57% | +26.3% |
Q4 2019 | $18,857,000 | +59.7% | 5,811,080 | +6.3% | 0.45% | +46.9% |
Q3 2019 | $11,805,000 | -9.9% | 5,465,156 | +31.0% | 0.30% | +4.5% |
Q2 2019 | $13,100,000 | -19.0% | 4,171,971 | -4.0% | 0.29% | -22.3% |
Q1 2019 | $16,164,000 | +24.9% | 4,345,083 | -2.6% | 0.38% | +13.9% |
Q4 2018 | $12,943,000 | +25.0% | 4,463,103 | +13.4% | 0.33% | +41.0% |
Q3 2018 | $10,354,000 | +1522.9% | 3,936,719 | +1343.0% | 0.23% | +1571.4% |
Q2 2018 | $638,000 | -73.5% | 272,811 | -66.8% | 0.01% | -72.5% |
Q1 2018 | $2,412,000 | -20.0% | 820,741 | -25.4% | 0.05% | -16.4% |
Q4 2017 | $3,016,000 | -20.0% | 1,100,518 | -1.1% | 0.06% | -20.8% |
Q3 2017 | $3,772,000 | +31.0% | 1,112,679 | +0.5% | 0.08% | +67.4% |
Q2 2017 | $2,879,000 | +2064.7% | 1,107,310 | +1790.3% | 0.05% | +2200.0% |
Q1 2017 | $133,000 | – | 58,578 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |